Vanguard Capital Management’s PharmaCyte Biotech PMCB Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.3K Hold
2,988
– – ﹤0.01% 3969
2026
Q2
$43.7K Buy
2,988
+279
+10% +$3.99K ﹤0.01% 3947
2026
Q1
$34.2K Buy
+2,709
New +$39.4K ﹤0.01% 3952

Other funds holding PMCB

Vanguard Capital Management's PMCB Position: Q3 2026 in Review

Vanguard Capital Management held its PharmaCyte Biotech (PMCB) position steady in Q3 2026 at 2,988 shares worth $23.3K. The position accounts for ﹤0.01% of the portfolio, ranked #3969.

Vanguard Capital Management first reported a position in PMCB in Q1 2026 and has held it in 3 quarters since. The position peaked at $43.7K in Q2 2026. 20 funds tracked by Wall St. Rank hold PMCB as of Q3 2026.

  • Vanguard Capital Management held 2,988 shares of PharmaCyte Biotech worth $23.3K as of Q3 2026.
  • Vanguard Capital Management left its PharmaCyte Biotech share count unchanged in Q3 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3969 holding.
  • Vanguard Capital Management first reported a position in PharmaCyte Biotech in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's PharmaCyte Biotech position peaked at $43.7K in Q2 2026.
  • 20 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.